The Gross Law Firm Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 – AGEN

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit due to alleged misleading statements about the effectiveness of their immuno-oncology products [1][2]. Group 1: Allegations - The complaint alleges that during the class period from January 23, 2023, to July 17, 2024, the defendants made materially false and misleading statements about the combination therapy of botensilimab and balstilimab [2]. - It is claimed that the effectiveness of the combination therapy was overstated, leading to inflated clinical results and regulatory and commercial prospects [2]. - As a result, the company's public statements were deemed materially false and misleading throughout the relevant period [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is November 5, 2024, and participation does not require appointment as a lead plaintiff [2]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - The Gross Law Firm emphasizes that there is no cost or obligation for shareholders to participate in the case [2].